| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
|
|
12-16-2019, 02:05 PM
|
#1 | ||
|
|||
|
Member
|
Georgetown has reported the results of their Nilotinib clinical trial. They may interpret the data differently, however, the results really are quite similar to the Northwestern trial. I believe they are hopping to get support for a phase 3. I honestly think, though, that given the limited amount of research dollars available, the funds would be better used to research the other three c-abl inhibitors that are going into trial. They all have better neurological profiles than nilotinib.
Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial | Movement Disorders | JAMA Neurology | JAMA Network |
||
|
 Reply With Quote
|
| "Thanks for this!" says: | jeffreyn (12-16-2019), soccertese (12-17-2019) |
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| New pharmacokinetics and biomarker data from the Georgetown Nilotinib trial | Parkinson's Disease | |||
| Nilotinib in Parkinson's Disease (NILO-PD) | Parkinson's Disease | |||
| Georgetown Receives FDA Clearance for Trial with Nilotinib in Alzheim | Parkinson's Disease | |||
| Nilotinib Parkinson Trial to begin this summer! | Parkinson's Disease | |||
| Six month follow up on Nilotinib trial. | Parkinson's Disease | |||
Hybrid Mode
